References
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. [Internet].
- American Cancer Society. Cancer facts & figures 2020. Atlanta, Ga: American Cancer Society; 2020.
- Kwan ML, Ergas IJ, Somkin CP, et al. Quality of life among women recently diagnosed with invasive breast cancer: the pathways study. Breast Cancer Res Treat. 2010;123:507–524. [Internet].
- Slamon D, Godolphin W, Jones L, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712. [Internet].
- Controlling Healthcare Costs While Promoting the Best Possible Health Outcomes [Internet]. [cited 2020 Aug 28]. Available from: http://www.acponline.org/advocacy/where_we_stand/policy/controlling_healthcare_costs.pdf.
- Douglas Scott R, Solomon SL, McGowan JE. Applying Economic Principles to Health Care - Volume 7, Number 2—April 2001 - Emerging Infectious Disease journal - CDC. Emerg Infect Dis. 2001 cited 2020 Aug 28;7:282–285. [Internet]. Available from: https://wwwnc.cdc.gov/eid/article/7/2/70-0282_article
- Scheunemann LP, White DB. The ethics and reality of rationing in medicine. Chest. 2011;140:1625–1632. [Internet]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0012369211606624
- Diaby V, Tawk R, Sanogo V, et al. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res Treat. 2015;151:27–40. [Internet].
- Smith V, Devane D, Begley CM, et al. Methodology in conducting a systematic review of systematic reviews of healthcare interventions. BMC Med Res Methodol. 2011;11:15. [Internet].
- PRISMA [Internet]. [cited 2020 Aug 28]]. Available from: http://www.prisma-statement.org/.
- Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017:j4008. [Internet]. DOI:10.1136/bmj.j4008.
- Jayasekera J, Mandelblatt JS. Systematic review of the cost effectiveness of breast cancer prevention, screening, and treatment interventions. J Clin Oncol. 2020;38:332–350.
- Gogate A, Rotter JS, Trogdon JG, et al. An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer. Breast Cancer Res Treat. 2019;174:343–355. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30603995
- de Andrade TS, Mosegui GBG, Miranda ES, et al. Trastuzumab in metastatic breast cancer: systematic review of cost-effectiveness analyses. Int J Pharm Pharm Sci. 2015;7:47–56.
- Nixon NA, Hannouf MB, Verma S. A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer. Eur J Cancer. 2018;89:72–81.
- Fleeman N, Bagust A, Boland A, et al. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. Health Technol Assess (Rockv). 2011;15. [Internet]. Available from: https://www.journalslibrary.nihr.ac.uk/hta/hta15420/
- Delea TE, Amdahl J, Chit A, et al. Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor–positive metastatic breast cancer in Canada. Curr Oncol. 2013;20:371. [Internet].;:. Available from. : http://www.current-oncology.com/index.php/oncology/article/view/1394
- Athanasakis K, Kyriopoulos J. A cost-effectiveness analysis of trastuzumab plus docetaxel vs. docetaxel alone for the treatment of HER2-positive metastatic breast cancer in the Greek healthcare setting. Forum Clin Oncol. 2012;3(4):28–34.
- Garrison LP, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value Heal. 2009;12:1118–1123. [Internet]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1098301510603178
- Elkin EB, Weinstein MC, Winer EP, et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2004;22:854–863. [Internet].
- Poncet B, Bachelot T, Colin C, et al. Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer. Am J Clin Oncol. 2008;31:363–368. [Internet]. Available from: http://journals.lww.com/00000421-200808000–00009
- Perez-Ellis C, Goncalves A, Jacquemier J, et al. Cost-effectiveness analysis of trastuzumab (Herceptin) in HER2-overexpressed metastatic breast cancer. Am J Clin Oncol. 2009;32:492–498. [Internet]. Available from: http://journals.lww.com/00000421-200910000–00008
- Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol. 2005;16:909–914. [Internet]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753419476503
- Lidgren M, Wilking N, Jönsson B, et al. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol (Madr). 2008;47:1018–1028. [Internet].
- Durkee BY, Qian Y, Pollom EL, et al. Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2–positive metastatic breast cancer. J Clin Oncol. 2016;34:902–909. [Internet].
- ISPOR - Cost-effectiveness analysis of pertuzumab for metastatic HER2-positive breast cancer in Japan [Internet]. [cited 2020 Aug 28]. Available from: https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-18th-annual-european-congress/cost-effectiveness-analysis-of-pertuzumab-for-metastatic-her2-positive-breast-cancer-in-japan.
- Beauchemin C, Letarte N, Mathurin K, et al. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada. J Med Econ. 2016:19:619–629. [Internet].
- Matter-Walstra KW, Dedes KJ, Schwenkglenks M, et al. Trastuzumab beyond progression: a cost-utility analysis. Ann Oncol. 2010;21:2161–2168. [Internet]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753419395493
- Neyt MJ, Albrecht JA, Clarysse B, et al. Cost-effectiveness of Herceptin ® : A standard cost model for breast-cancer treatment in a Belgian university hospital. Int J Technol Assess Health Care. 2005;21:132–137. [Internet]. Available from: https://www.cambridge.org/core/product/identifier/S0266462305050178/type/journal_article
- Machado ET. Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective. Breast Cancer (Dove Med Press). 2012;4:173–182.
- Delea TE, Tappenden P, Sofrygin O, et al. Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab. Eur J Heal Econ. 2012;13:589–603. [Internet].
- Chicaiza-Becerra L, Garcia-Molina M, Gamboa O, et al. ErbB2+ metastatic breast cancer treatment after progression on trastuzumab: a cost-effectiveness analysis for a developing country. Rev Salud Publica (Bogota). 2014;16(2):270e80.
- Le QA, Hay JW. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer. 2009;115:489–498. [Internet].
- Le QA, Bae YH, Kang JH. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. Breast Cancer Res Treat. 2016;159:565–573. [Internet].
- Diaby V, Ali AA, Williams KJ, et al. Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. Breast Cancer Res Treat. 2017;166:951–963. [Internet].
- Diaby V, Adunlin G, Ali AA, et al. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat. 2016;160:187–196. [Internet].
- Sculpher M, Fenwick E, Claxton K. Assessing Quality in Decision Analytic Cost-Effectiveness Models. Pharmacoeconomics. 2000;17:461–477. [Internet].
- Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation:report of the ISPOR task force on good research practices—modeling studies. Value Heal. 2003;6:9–17. [Internet]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1098301510601283
- Kim JJ, Tosteson AN, Zauber AG, et al. Cancer models and real-world data: better together: table 1. J Natl Cancer Inst. 2016;108:djv316. [Internet].
- Pouwels XGLV, Ramaekers BLT, Joore MA. Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer. Breast Cancer Res Treat. 2017;165:485–498. [Internet].
- Saura C, Oliveira M, Feng Y-H, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020:JCO.20.00147. [Internet]. DOI:10.1200/JCO.20.00147.
- Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610–621. [Internet].
- Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382:597–609. [Internet].
- Arteaga CL, Sliwkowski MX, Osborne CK, et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012;9:16–32. [Internet]. Available from: http://www.nature.com/articles/nrclinonc.2011.177
- John M, Hinke A, Stauch M, et al. Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines-a phase II multipractice study. BMC Cancer. 2012;12:165. [Internet].
- Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2014;32:2078–2099. [Internet].
- Cameron D, Casey M, Oliva C, et al. Lapatinib plus capecitabine in women with HER‐2–positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist. 2010;15:924–934. [Internet].
- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792. [Internet].
- Swain S, Kim S, Cortes J. Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). Annals of Oncology. 2014;Sep 1;25:v1.
- Tanaka S, Tanaka S, Kawakami K. Methodological issues in observational studies and non-randomized controlled trials in oncology in the era of big data. Jpn J Clin Oncol. 2015;45:323–327. [Internet].
- Li J, Vachani A, Epstein A, et al. A doubly robust approach for cost-effectiveness estimation from observational data. Stat Methods Med Res. 2018;27:3126–3138. [Internet].
- Diaby Vakaramoko, Ali AA, Montero AJ. Value assessment frameworks in the United States: a call for patient engagement. Pharmacoecon Open. 2019;3:1–3. [Internet].